BeStock  
Stocks › Biotechnology › PHAT

Phathom Pharmaceuticals PHAT

US equityMarket cap rank #3679Biotechnology
$6.81 +$0.03 (+0.44%)
Market closed · Oct 8, 7:20 am ET · Last extended-hours $6.80 -0.15%
Open$6.87
Prev close$6.78
Day range$6.60 – $7.03
Volume1.63M
Market cap$550.94M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$74.27M+88.0% YoY
Operating profit-$3.97M+93.4% YoY
Net profit-$17.58M+76.8% YoY
Diluted EPS-$0.21+80.0% YoY
Free cash flow-$1.97M+96.9% YoY
Operating cash flow-$1.93M

Revenue, last 8 quarters

$16.4MSep '24$29.7MDec '24$28.5MMar '25$39.5MJun '25$49.5MSep '25$57.6MDec '25$58.3MMar '26$74.3MJun '26

Net profit, last 8 quarters

$-85.6MSep '24$-74.5MDec '24$-94.3MMar '25$-75.8MJun '25$-30.0MSep '25$-21.1MDec '25$-30.4MMar '26$-17.6MJun '26

Diluted EPS by quarter

-1.32Sep '24-1.05Dec '24-1.31Mar '25-1.05Jun '25-0.41Sep '25-0.29Dec '25-0.37Mar '26-0.21Jun '26

Free cash flow by quarter

$-63.6MSep '24$-63.5MDec '24$-84.9MMar '25$-62.8MJun '25$-14.1MSep '25$-5.1MDec '25$-15.7MMar '26$-2.0MJun '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$682.0KFY23$55.3MFY24$175.1MFY25

Profitability & balance sheet

Gross margin82.9%
Operating margin-17.0%
Net margin-41.3%
Return on assets-34.3%
Current ratio1.92
Liabilities / assets205.3%
Cash & investments$182.48M
Total debt$166.44M
Net cash (debt)$16.04M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $74.27M $58.30M $175.11M $57.58M –
Total Operating Revenue $74.27M $58.30M $175.11M $57.58M $49.50M
Cost of Revenue $15.10M $12.00M $22.60M $7.65M $6.19M
Gross Profit $59.18M $46.31M $152.51M $49.94M $43.31M
Operating Expense $63.14M $61.78M $312.50M $55.86M $58.59M
Selling and Admin Expenses $55.33M $54.01M $279.72M $48.37M $51.56M
Research & Development $7.81M $7.77M $32.78M $7.49M $7.03M
Operating Profit -$3.97M -$15.48M -$159.99M -$5.93M -$15.27M
Net Non-Operating Interest Income (Expense) -$13.59M -$14.06M -$61.07M -$15.22M -$14.70M
Non-Operating Interest Income $1.51M $1.74M $7.04M $1.20M $1.41M
Non-Operating Interest Expense $15.10M $15.80M $68.12M $16.42M $16.11M
Other Income (Expense) -$24,000.00 -$831,000.00 -$190,000.00 -$5,000.00 -$7,000.00
Other Non-Operating Income (Expenses) -$24,000.00 -$831,000.00 -$190,000.00 -$5,000.00 -$7,000.00
Pretax Profit -$17.58M -$30.37M -$221.25M -$21.15M -$29.97M
Net Profit -$17.58M -$30.37M -$221.25M -$21.15M -$29.97M
Profit from Continuing Operations -$17.58M -$30.37M -$221.25M -$21.15M -$29.97M
Net Income to Parent Company -$17.58M -$30.37M -$221.25M -$21.15M -$29.97M
Net Income to Common Stockholders -$17.58M -$30.37M -$221.25M -$21.15M -$29.97M
Basic EPS -$0.21 -$0.37 -$3.03 -$0.29 -$0.41
Diluted EPS -$0.21 -$0.37 -$3.03 -$0.29 -$0.41

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $327.08M $305.12M $259.15M $259.15M $240.29M
Total Current Assets $295.92M $276.57M $228.97M $228.97M $207.78M
Cash and Cash Equivalents & Short-Term Investments $182.48M $180.90M $129.97M $129.97M $135.16M
-Cash and Cash Equivalents $182.48M $180.90M $129.97M $129.97M $135.16M
Receivables $97.42M $80.72M $78.13M $78.13M $55.79M
-Accounts Receivable $97.42M $80.72M $78.13M $78.13M $55.79M
Inventory $7.71M $6.51M $5.52M $5.52M $3.61M
Other Current Assets $8.30M $8.44M $15.35M $15.35M $13.23M
Total Non-Current Assets $31.16M $28.55M $30.18M $30.18M $32.51M
Net PPE $3.38M $3.52M $3.67M $3.67M $3.85M
-Gross PPE $3.38M $3.52M $7.14M $7.14M $3.85M
Other Non-Current Assets $27.78M $25.03M $26.51M $26.51M $28.66M
Total Liabilities $671.35M $642.08M $697.32M $697.32M $662.82M
Total Current Liabilities $153.78M $125.04M $132.04M $132.04M $93.12M
Payables $5.36M $6.37M $4.98M $4.98M $1.08M
-Accounts Payable $5.36M $6.37M $4.98M $4.98M $1.08M
Current Accrued Expenses $97.16M $75.78M $76.82M $76.82M $52.32M
Short-Term Debt and Capital Lease Obligation $670,000.00 $667,000.00 $648,000.00 $648,000.00 $591,000.00
-Current Capital Lease Obligation $670,000.00 $667,000.00 $648,000.00 $648,000.00 $591,000.00
Other Current Liabilities $37.28M $33.02M $34.75M $34.75M $24.34M
Total Non-Current Liabilities $517.57M $517.03M $565.27M $565.27M $569.70M
Long Term Debt and Capital Lease Obligation $166.44M $165.64M $211.15M $211.15M $209.22M
-Long Term Debt $164.59M $163.68M $209.09M $209.09M $207.09M
-Long Term Capital Lease Obligation $1.86M $1.96M $2.07M $2.07M $2.12M
Other Non-Current Liabilities $351.13M $351.40M $354.12M $354.12M $360.48M
Total Equity -$344.27M -$336.96M -$438.17M -$438.17M -$422.53M
Stockholders' Equity -$344.27M -$336.96M -$438.17M -$438.17M -$422.53M
Capital Stock $8,000.00 $7,000.00 $6,000.00 $6,000.00 $6,000.00
-Common Stock $8,000.00 $7,000.00 $6,000.00 $6,000.00 $6,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.19B $1.18B $1.05B $1.05B $1.04B
Retained Earnings -$1.53B -$1.51B -$1.48B -$1.48B -$1.46B
Less: Treasury Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Accumulated Depreciation – – -$3.48M -$3.48M –

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$1.93M -$15.65M -$166.78M -$5.00M -$14.12M
Net cash flow from continuing operations -$1.93M -$15.65M -$166.78M -$5.00M -$14.12M
Net Income from Continuing Operations -$17.58M -$30.37M -$221.25M -$21.15M -$29.97M
Gain/Loss from Continuing Operations $0.00 $829,000.00 – – –
Depreciation & Depletion & Amortization $114,000.00 $110,000.00 $633,000.00 $128,000.00 $156,000.00
Other Non-Cash Items $6.19M $6.70M $37.22M $6.90M $7.96M
Change in Working Capital $2.63M $1.55M -$12.38M $4.05M -$1.56M
-Change in Receivables -$16.70M -$2.60M -$39.33M -$22.34M -$4.53M
-Change in Inventory -$3.96M $665,000.00 -$11.78M $2.00M $395,000.00
-Change in Prepaid Assets $132,000.00 $6.92M $5.51M -$2.13M $1.39M
-Change in Payables and Accrued Expense $23.16M -$3.28M $34.23M $27.64M $1.12M
-Change in Other Current Assets $0.00 -$171,000.00 -$1.22M – –
-Change In Other Working Capital -$5,000.00 $10,000.00 $222,000.00 $90,000.00 $66,000.00
Net cash flow from investing -$44,000.00 -$61,000.00 -$229,000.00 -$87,000.00 -$27,000.00
Net Cash Flow from Continuing Investing Activities -$44,000.00 -$61,000.00 -$229,000.00 -$87,000.00 -$27,000.00
Net PPE Purchase and Sale -$44,000.00 -$61,000.00 -$229,000.00 -$87,000.00 -$27,000.00
Financing Cash Flow $3.55M $66.64M -$288,000.00 -$97,000.00 -$271,000.00
Net Cash Flow from Continuing Financing Activities $3.55M $66.64M -$288,000.00 -$97,000.00 -$271,000.00
Net Issuance Payments Of Debt $0.00 -$55.80M $0.00 $0.00 $0.00
Net Common Stock Issuance $0.00 $121.97M $0.00 $0.00 $0.00
Proceeds from Stock Option Exercised $3.55M $591,000.00 $1.64M $1.27M $293,000.00
Net Other Financing Charges $0.00 -$128,000.00 -$1.93M -$1.36M –
Ending Cash Balance $185.34M $183.77M $132.83M $132.83M $138.02M
Net Change in Cash $1.58M $50.93M -$167.29M -$5.19M -$14.41M
Beginning Cash Balance $183.77M $132.83M $300.13M $138.02M $152.43M
Free Cash Flow -$1.97M -$15.71M -$167.00M -$5.09M -$14.14M

Discussion

No comments yet — be the first to weigh in on PHAT.

Leave a comment

Scroll to Top